• Yafit Stark, Vice President, Chief Clinical Officer, Teva, Israel (bio)
• Jean Pierre Bizzari, Senior Vice President Oncology, Celgene, USA (bio)
• Ismail Jatoi, University of Texas Health Science Center USA, Dale H. Dorn Chair in Surgery, Professor and Chief Division of Surgical Oncology Department of Surgery
  
• Alan Barge, Chief Medical Officer, Aslan Pharmaceuticals, UK (bio)
  
• Rob Berg, Director Experimental Medicine Oncology, MSD, The Netherlands (bio)
  
• Matteo Dionisi, Medical Director, Ipsen, Italy (bio)
  
• Jean-Pierre Armand, General Director of the Institute Claudius Regaud, Touleouse France, Member of International Boards of the AACR, Scientific committee of ASCO and AACR, Board clinical trials at INCa, Chairman of the president nominating committee of ESMO (bio)
  
• Miro Venturi, Senior Biomarker & Experimental Medicine Leader, Roche, Germany (bio)
  
• Yasser Mostafa Kamel, Senior Clinical Development Director Oncology, GlaxoSmithKline, UK (bio)
  
• Oscar Della Pasqua, Director Clinical Pharmacology & Discovery Medicine, Honorary Lecturer at University College London, GSK, UK
• Hagop Youssoufian, Executive Vice President /Chief Medical Officer – Ziopharm, USA (bio)
  
• Nicolas Leupin, Director, Clinical Research & Development EMEA, Celgene, Switzerland (bio)
  
• Cyril Konto, Medical Director, Gobal Clinical Research Oncology, BMS, France
• Brian Moulton, ICORG, Ireland, CEO

Our Expert Advisors:

• Rob Berg, Director Experimental Medicine Oncology, MSD, The Netherlands (bio)
• Stefano Ferrara, Clinical Research Scientist, Celgene, Switzerland
• Thomas Pepper, Clinical Operations Leader – Oncology, Roche, UK
• Miro Venturi, Senior Biomarker & Experimental Medicine Leader, Roche, Germany (bio)
• Chiara Zilocchi, Oncology Clinical Study Director, Sanofi Aventis, Italy
• Roberto M. Carlesi, ImClone Systems Unit Medical Director, Eli Lilly, Italy